FOLH1 and neoplasm: Limited efficacy of PSMA‐targeted formulations, modest trial outcomes with liposomal drugs, and persistent barriers such as hypoxia, tumor heterogeneity, and regulatory complexity highlight that widespread clinical adoption is not yet achievable.